Diseaseinfopack: Pre-pandemic Vaccines
VacZine Analytics
March 1, 2009 70 Pages - SKU: VZAN2213950
|
|
Highly pathogenic avian influenza H5N1 has caused high mortality in poultry/wild birds and occasionally infects humans in close contact with around 60% of cases (408) so far being fatal. As of February 27th 2009 confirmed H5N1 Avian influenza deaths in humans have reached 256, a significant increase upon 2004 when measurements began.
This expert report provides a comprehensive up-to-date critical review of current global pandemic preparedness and planning with regard to the overarching World Health Organisation (WHO) objectives/strategies and key features of major Western countries pandemic preparedness plans. A particular emphasis is placed on the role of pre-pandemic vaccines, pandemic “specific” vaccines relative to other pandemic countermeasures e.g. antivirals. The report captures the viewpoints of 5 recognised global opinion leaders and discusses current arguments for and against “early” pre-pandemic H5 priming. Target populations and vaccination strategies are discussed along with potential impacts on seasonal influenza vaccination.
|
- Foreword
- Contents
- Experts interviewed as part of this research
- Executive summary
- Pandemic preparedness: Role of WHO
- Expert viewpoints: pandemic preparedness
- WHO Strategic action plan
- WHO: Six stages of pandemic alert
- Stages of pandemic alerts: revisions for 2008
- US HHS stockpile goals for pandemic preparedness
- Expert viewpoints: US preparedness
- US HHS funding for influenza pandemic preparedness 2004-2008
- US pandemic vaccine(s): review of objectives
- Pre-pandemic vaccine: implementation (US)
- US HHS awards for cell-based influenza vaccines
- US pandemic vaccine(s): points to note
- US HHS planning: Congressional Budget Office (CBO) review
- US framework for targetting pandemic specific vaccine
- US estimated number in vaccine target groups
- US estimated numbers in vaccine tiers
- Expert viewpoints: subcategorizing the population
- Sub prioritization of tier 1
- Possible phasing of pandemic vaccines
- Expert viewpoints: release of stockpile (US) and general
- Canada: pandemic specific vaccine objectives
- Canada: framework for targetting pandemic specific vaccine
- Canada: factors influencing subgroup prioritization
- Canada: pre-pandemic vaccine status
- Expert viewpoints: UK preparedness
- UK: framework for targetting pandemic specific vaccine
- UK: anticipated demand of pandemic specific vaccine
- UK: implementation of pandemic specific vaccination
- UK: pre-pandemic vaccination
- Expert Viewpoints: UK pandemic preparedness
- France: summary of pandemic vaccine planning
- Spain: summary of pandemic vaccine planning
- Italy: summary of pandemic vaccine planning
- Australia and pandemic plan: phases of health response
- Australia: summary of pandemic vaccine planning
- Japan: summary of pandemic vaccine planning
- Pre-pandemic vaccine stockpiling: country summary
- Advance supply commitments: country summary
- Expert Viewpoints: comments on advanced supply agreements
- “Early” pre-pandemic priming: drivers and resistors
- Expert Viewpoints: “early” priming strategy
- Expert Viewpoints: combining H5 with seasonal vaccine
- “Early” pre-pandemic priming - possible rollout strategy
- Pandemic vaccine: impacts on seasonal market
- Pre-Pandemic planning: brief comments on the business sector
- Pre-Pandemic planning: brief comments on a consumer model
- Appendix I - US HHS: summary of planning actions to date
- Appendix I - Bibliography
- Appendix II - About VacZine Analytics
- Disclaimer
Share this report
Other tasks Related Markets Pandemic Vaccines Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
